The creation of high-quality, innovative small molecule leads is a continual challenge in drug discovery. Against a background of increasing cost, the rate of drug discovery has remained stagnant for over 60 years. Improving research and development productivity is a considerable obstacle for the pharmaceutical sector. To address these challenges, innovative methods are crucial. Curia addresses this in a novel way through CLC.View resource
More from Curia
The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate fro...